Neuralink Competitors: Every Company Building Brain Implants
Neuralink is not the only company building brain implants. At least 10 other companies are developing implantable brain-computer interfaces across four distinct approaches: intracortical (electrodes inside brain tissue), endovascular (electrodes inside blood vessels), electrocorticographic (electrodes on the brain surface), and minimally invasive architectures. This page tracks every Neuralink competitor with implant-grade technology, their funding, FDA status, surgical approach, and target indications.
Complete Brain Implant Company Directory
| Company | Approach | Indications | Funding | FDA Status |
|---|---|---|---|---|
| Neuralink Corp | Invasive (intracortical) | ALS, quadriplegia, spinal cord injury, blindness | $1.3B+ | IDE (PRIME study) + Breakthrough Device (Blindsight) |
| Synchron | Endovascular | ALS, severe paralysis, motor neuron disease | $345M | Breakthrough Device Designation |
| Precision Neuroscience | Minimally invasive (ECoG) | Epilepsy monitoring, paralysis, motor control | $183M | 510(k) cleared (30-day implant) |
| Blackrock Neurotech | Invasive (intracortical) | Paralysis, ALS, research | $250M+ | IDE (multiple studies) |
| Paradromics | Invasive (intracortical) | ALS, paralysis, speech restoration | $127M | IDE (in preparation) |
| Science Corporation | Invasive (visual cortex) | Blindness, visual prosthesis | $490M | Pre-clinical |
| Motif Neurotech | Minimally invasive | Depression, neurological disorders | $30M+ | Pre-clinical |
| NeuroPace | Invasive (responsive neurostimulation) | Epilepsy (FDA-approved) | $250M+ | PMA approved (RNS System) |
| ONWARD Medical | Invasive (spinal cord stimulation) | Spinal cord injury, paralysis | CHF 100M+ | Breakthrough Device Designation |
| INBRAIN Neuroelectronics | Invasive (graphene) | Parkinson's, epilepsy | $60M+ | Pre-clinical |
| BrainGate Consortium | Invasive (intracortical) | Paralysis, ALS (research) | — | IDE (BrainGate2 trial) |
Non-Invasive BCI Competitors
Beyond implantable devices, several companies compete with Neuralink using non-invasive approaches that require no surgery. These trade bandwidth and precision for safety and accessibility, targeting consumer and enterprise markets rather than clinical paralysis patients.
Neuralink Has Serious Competition
Neuralink has the most funding ($1.29B+), the highest electrode count (1,024), and the most media attention. But it is not alone. Synchron implanted humans four years before Neuralink did. Precision Neuroscience matches Neuralink's electrode count with a less invasive approach. Blackrock Neurotech has the longest track record of chronic human BCI implants (since 2004 via BrainGate). Science Corporation has raised nearly $500M for visual prosthetics.
The BCI implant market is a multi-company race, not a monopoly. Different approaches will likely serve different patient populations.
Frequently Asked Questions
Company data sourced from SEC filings, Crunchbase, FDA device databases, ClinicalTrials.gov, and verified company disclosures. Last verified: April 2026.